| Date |
Research Question / Title |
Unique ID |
Research Team |
|
June 6, 2022
|
What is known about hybrid immunity to COVID-19?
|
INF220501 RR Table
|
Infectious Disease
|
|
June 6, 2022
|
What is known about hybrid immunity to COVID-19?
|
INF220501 RR
|
Infectious Disease
|
|
May 18, 2022
|
What is known about hybrid immunity to COVID-19?
|
INF220501 ESR
|
Infectious Disease
|
|
March 10, 2022
|
What is the safety/efficacy of the Novavax COVID-19 vaccine?
|
EOC220302 RR Table
|
EOC
|
|
March 10, 2022
|
What is the safety/efficacy of the Novavax COVID-19 vaccine?
|
EOC220302 RR
|
EOC
|
|
March 4, 2022
|
What is the safety/efficacy of the Novavax vaccine?
|
EOC220302 ESR
|
EOC
|
|
January 12, 2022
|
In real world settings, what is the validity of Rapid Antigen Tests (RATs) in identifying SARS-CoV-2 and how well do they predict disease?
|
EOC211201 RR Table
|
EOC
|
|
January 12, 2022
|
In real world settings, what is the validity of Rapid Antigen Tests (RATs) in identifying SARS-CoV-2 and how well do they predict disease?
|
EOC211201 RR
|
EOC
|
|
January 5, 2022
|
Omicron Variant: In real world settings, what is the validity of RATs in identifying COVID-19 (sensitivity, specificity), and how well do they predict disease (positive and negative predictive values)?
|
EOC211201-02 ESR
|
EOC
|
|
December 29, 2021
|
In real world settings, what is the validity of RATs in identifying COVID-19 (sensitivity, specificity), and how well do they predict disease (positive and negative predictive values)?
|
EOC211201 ESR
|
EOC
|
|
October 7, 2021
|
What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general
population?
|
EOC210902 RR Table
|
EOC
|
|
October 7, 2021
|
What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population?
|
EOC210902 RR
|
EOC
|
|
September 29, 2021
|
What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population?
|
EOC210902 ESR
|
EOC
|
|
April 21, 2021
|
What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations?
|
EOC210302 RR
|
EOC
|
|
April 21, 2021
|
What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations?
|
EOC210302 RR Table
|
EOC
|
|
April 1, 2021
|
What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations?
|
EOC210302 ESR
|
EOC
|
|
August 27, 2020
|
What laboratory surveillance testing strategies are effective for COVID-19 in school settings?
|
PH082501 RR
|
Public Health
|
|
August 25, 2020
|
What laboratory surveillance testing strategies are effective for COVID-19 in school settings?
|
PH082501-01 ESR
|
Public Health
|
